title: Assessing the effects of ketorolac and acetazolamide  on macular thickness by optical coherence tomography  following cataract surgery.
abstract: We aimed to evaluate the efficacy of topical ketorolac 0.5 % solution and oral acetazolamide 250 mg/day delivery during the first month after uneventful phacoemulsification surgery by measuring the macular thickness using optical coherence tomography. Our nonmasked randomized prospective study comprised 87 eyes of 80 patients. Complete follow-up was achieved on 84 eyes of 77 eligible patients. Postoperatively, the patients were divided into three groups. One group received ketorolac 0.5 %, the other group received acetazolamide 250 mg/day, and the control group was given no agent. Macular thickness and volume were measured at 1 week and 1 month after surgery by optical coherence tomography. Foveal thickness, parafoveal thickness, and perifoveal thickness were determined to be significantly elevated at postoperative 1 week and 1 month in the control group. Foveal, perifoveal, and parafoveal volumes were also significantly high at postoperative week 1 and month 1 in the control group. There was no significant difference between the ketorolac and acetazolamide groups. The correlation analysis between best-corrected visual acuity, and volume and thickness revealed a negative correlation in the acetazolamide group. Use of acetazolamide after cataract surgery is as effective as ketorolac on macular thickness and volume.
authors.forename: Ece
authors.initials: E
authors.lastname: Turan-Vural
authors.forename: Elvin
authors.initials: E
authors.lastname: Halili
authors.forename: Didem
authors.initials: D
authors.lastname: Serin
mesh_terms: D000086:Acetazolamide / Q000494:pharmacology* / Q000627:therapeutic use; D000284:Administration, Oral; D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology* / Q000627:therapeutic use; D002257:Carbonic Anhydrase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D020910:Ketorolac / Q000494:pharmacology* / Q000627:therapeutic use; D008266:Macula Lutea / Q000187:drug effects* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D018918:Phacoemulsification; D011183:Postoperative Complications / Q000517:prevention & control; D011446:Prospective Studies; D041623:Tomography, Optical Coherence; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D002257:Carbonic Anhydrase Inhibitors; D000086:Acetazolamide; D020910:Ketorolac
references.citation: Am J Ophthalmol. 1991 Nov 15;112(5):514-9
references.pmid: 1951587
references.citation: Br J Ophthalmol. 2005 Nov;89(11):1420-2
references.pmid: 16234444
references.citation: Ophthalmology. 1998 Mar;105(3):397-405
references.pmid: 9499767
references.citation: Eur J Ophthalmol. 2008 Nov-Dec;18(6):1011-3
references.pmid: 18988178
references.citation: Neuro Endocrinol Lett. 2009;30(5):610-4
references.pmid: 20035257
references.citation: Arch Ophthalmol. 1988 Sep;106(9):1190-5
references.pmid: 3415543
references.citation: Surv Ophthalmol. 2002 Aug;47 Suppl 1:S203-18
references.pmid: 12204717
references.citation: J Cataract Refract Surg. 1999 Nov;25(11):1492-7
references.pmid: 10569164
references.citation: Ophthalmology. 2000 Mar;107(3):593-9
references.pmid: 10711901
references.citation: Br J Ophthalmol. 2007 Jun;91(6):743-5
references.pmid: 17215269
references.citation: Ophthalmology. 1998 Feb;105(2):360-70
references.pmid: 9479300
references.citation: Ophthalmology. 1990 Oct;97(10):1253-8
references.pmid: 2243674
references.citation: Curr Eye Res. 2007 Mar;32(3):241-7
references.pmid: 17453944
references.citation: Curr Opin Ophthalmol. 2009 Jan;20(1):46-51
references.pmid: 19093330
references.citation: Invest Ophthalmol Vis Sci. 1992 Mar;33(3):504-7
references.pmid: 1544778
references.citation: Doc Ophthalmol. 1986 Nov 15;63(4):375-81
references.pmid: 3492349
references.citation: Clin Exp Ophthalmol. 2006 Mar;34(2):124-9; quiz 194
references.pmid: 16626425
references.citation: Doc Ophthalmol. 1999;97(3-4):387-97
references.pmid: 10896355
references.citation: Histol Histopathol. 1995 Jan;10(1):141-54
references.pmid: 7756735
references.citation: Arch Ophthalmol. 1995 Aug;113(8):1019-29
references.pmid: 7639652
references.citation: J Cataract Refract Surg. 2008 Jan;34(1):64-9
references.pmid: 18165083
references.citation: Retina. 2010 Jun;30(6):917-23
references.pmid: 20168270
references.citation: J Fr Ophtalmol. 2005 Dec;28(10):1027-31
references.pmid: 16395193
references.citation: Br J Ophthalmol. 1994 Jan;78(1):4-7
references.pmid: 8110697
references.citation: J Cataract Refract Surg. 1999 Feb;25(2):256-61
references.pmid: 9951674
references.citation: Graefes Arch Clin Exp Ophthalmol. 2007 Dec;245(12):1765-71
references.pmid: 17619896
references.citation: Surv Ophthalmol. 2004 Sep-Oct;49(5):470-90
references.pmid: 15325193
references.citation: Curr Eye Res. 2009 Dec;34(12):1036-41
references.pmid: 19958122
references.citation: Ophthalmology. 1987 Sep;94(9):1134-9
references.pmid: 3684231
references.citation: J Cataract Refract Surg. 2004 Apr;30(4):752-60
references.pmid: 15093635
references.citation: J Cataract Refract Surg. 2010 Jan;36(1):66-72
references.pmid: 20117707